Results 151 to 160 of about 4,200 (201)

Blood Pressure Management Strategies and Podocyte Health. [PDF]

Am J Hypertens
Semenikhina M, Mathew RO, Barakat M, Van Beusecum JP, Ilatovskaya DV, Palygin O.   +5 more
europepmc   +1 more source

Confident but unsupported: auditing large language models against supplied evidence boundaries in drug-induced liver injury assessment. [PDF]

Front Public Health
Shi J, Ma Y, Liu Y, Shi B.
europepmc   +1 more source

Acute Kidney Injury as a Safety End Point in Non-Acute Kidney Injury Clinical Trials. [PDF]

J Am Soc Nephrol
McCoy IE, Chertow GM.
europepmc   +1 more source

Effective Management of Hypertensive Emergencies with Aliskiren Treatment in a Patient before and after Introducing Hemodialysis Secondary to Scleroderma Renal Crisis-like Condition under Corticosteroid Treatment for Sjögren Syndrome-associated Multiple Mononeuropathy. [PDF]

Intern Med
Yamazaki O, Murakawa M, Ochiai F, Fujii W, Asakawa S, Nagura M, Arai S, Tamura Y, Ohashi R, Shibata S, Fujigaki Y.   +10 more
europepmc   +1 more source

Spontaneous and evoked angiotensin II sniffer cell activity in the lamina terminalis in vitro.

Am J Physiol Regul Integr Comp Physiol
Farmer GE, Cunningham JT.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aliskiren

Drugs, 2007
Aliskiren (CGP-60536 or SPP100) is the first oral direct renin inhibitor and the first new class of antihypertensive agents to be introduced in more than a decade. Aliskiren taken once a day, alone or in combination with other antihypertensive agents, has been shown to be effective in reducing blood pressure and is generally well tolerated. Based on an
James E Frampton
exaly   +11 more sources

Aliskiren [PDF]

Circulation, 2008
Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg, there are dose-related falls in blood pressure comparable to those seen with other major classes of antihypertensive drugs and that these falls are
Morris Brown
exaly   +6 more sources

Efficacy of Aliskiren/Hydrochlorothiazide Single-Pill Combinations in Aliskiren Non-Responders

Blood Pressure, 2008
Objectives. To evaluate the efficacy, safety and tolerability of a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT) in patients with hypertension and an inadequate BP response to aliskiren monotherapy (mean ...
Giuseppe Lembo, Jack Zhang
exaly   +2 more sources

Aliskiren

Drugs, 2010
Sean Duggan, Monique P Curran
exaly   +2 more sources

Aliskiren Accumulates in Renin Secretory Granules and Binds Plasma Prorenin

Hypertension, 2008
The vascular effects of aliskiren last longer than expected based on its half life, and this renin inhibitor has been reported to cause a greater renin rise than other renin-angiotensin system blockers.
Naomi D L Fisher, Manne Krop, Jeanette M G van Gool   +2 more
exaly   +2 more sources